1,031 results on '"Massie, Barry M."'
Search Results
202. The PROTECT Pilot Study: A Randomized, Placebo-Controlled, Dose-Finding Study of the Adenosine A1 Receptor Antagonist Rolofylline in Patients With Acute Heart Failure and Renal Impairment
203. Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival
204. Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure
205. Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance
206. Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial
207. Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia
208. Abstract 3640: Diabetes Mellitus is Associated with Increased Risk of Fatal and Non-Fatal Cardiovascular Events in Heart Failure Patients with Preserved Ejection Fraction - Findings From the Irbesartan in Heart Failure with Preserved Systolic Function Trial
209. Abstract 3148: Atrial Fibrillation Is Associated With Increased Risk Of Fatal And Non-fatal Cardiovascular Events In Patients With Heart Failure And Preserved Ejection Fraction - Findings From The Irbesartan In Heart Failure With Preserved Systolic Function Trial (I-PRESERVE)
210. Trends in Heart Failure Hospitalization Rate and Outcome in the United States
211. Response to Letter Regarding Article, “Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study”
212. The Utility of Gestures in Patients with Chest Discomfort
213. Effects of the Adenosine A1 Receptor Antagonist, KW-3902, Alone and in Combination with Furosemide, on Diuresis and Renal Function in Hospitalized Acutely Decompensated Heart Failure Patients with Renal Impairment or Refractory to Maximum Dose of Conventional Diuretics: Two Randomized, Double-Blind, Placebo-Controlled Studies.
214. Heart Failure in Community Practice: Relationship to Age and Sex in a ?-Blocker Registry
215. Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure
216. Chronic Heart Failure: A Report From the Dartmouth Diastole Discourses
217. The Year in Heart Failure 2005
218. Acute Heart Failure Syndromes
219. The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and Design
220. Aspirin Use in Chronic Heart Failure
221. Heart Failure Trials: Are They Becoming Impractical?
222. Nesiritide and Worsening of Renal Function
223. Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients
224. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study
225. The year in heart failure: 2004
226. Risk stratification after hospitalization for decompensated heart failure
227. β-blocker therapy for heart failure outside the clinical trial setting: Findings of a community-based registry
228. The Clinical Challenge of Cardiorenal Syndrome
229. Cardiac Resynchronization for Heart Failure
230. Renal Function, Digoxin Therapy, and Heart Failure Outcomes
231. The Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristics
232. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients11Guest Editor for this manuscript was Peter M. Okin, MD, New York Hosptial-Cornell Medical Center, New York, NY.
233. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure
234. A comment on COMET: how to interpret a positive trial?
235. The dilemma of drug development for heart failure: when is the time to initiate large clinical trials?
236. Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry
237. Beta-blockers in patients with left ventricular ejection fraction >40%: results from a community-based registry
238. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study
239. Chronic heart failure is not an independent cause of anemia
240. Titration, tolerability, and results of beta-blocker therapy for heart failure in the community: Findings of a community-based registry
241. Failure of benefit and early hazard of bucindolol for Class IV heart failure
242. Aligning quality and payment for heart failure care: Defining the challenges
243. Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function
244. Heart failure: how big is the problem? who are the patients? what does the future hold?
245. Improving Guideline Adherence
246. Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION
247. Natriuretic peptide measurements for the diagnosis of “nonsystolic” heart failure
248. Negative, neutral, and discordant results: What should an editor do?
249. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization
250. Specialty care for heart failure: Does it improve outcomes?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.